11 May Personalized Medicine: Caris Life Sciences Offers DNA and RNA Cancer Profiling
MedicalResearch.com Interview with:
David Spetzler, M.S., Ph.D., M.B.A.
President and Chief Scientific Officer
Caris Life Sciences
MedicalResearch.com: What is the background for this announcement (WES)?
Response: The announcement is about the launch of Caris’ latest molecular profiling test, called MI ExomeTM. MI Exome a next-generation sequencing-based assay analyzing the whole exome of 22,000 DNA genes. It is unique in that it will be run on every patient and will deliver unprecedented detail into the genomic characteristics of cancers, which will greatly improve our ability to understand cancer and provide insights needed to help physicians and patients make more informed treatment decisions that improve outcomes.
MedicalResearch.com: How does the this test differ from other available exome testing? How does it complement other Caris’ profiling tools?
Response: There are essentially no other labs in the world that offer both whole exome (DNA) and whole transcriptome (RNA) testing for every patient and that have the same clinical reach as Caris. It’s one thing for a small clinical or research oriented lab to say they offer these tests and another thing to offer these tests for every patient and with the clinical reach that Caris has across the U.S. and via our network across the world. These tests are part of the Caris comprehensive molecular profiling approach which includes DNA, RNA, proteins – and now molecular Artificial Intelligence (AI) offerings – all as part of our standard menu offering.
MedicalResearch.com: What should readers take away from your report?
Response: Oncologists need a trusted tumor profiling partner to provide reliable, high-quality molecular information to guide more precise and individualized treatment decisions. Caris provides the most comprehensive and informative molecular profile for cancer patients in a clinical offering that’s ever been available.
MedicalResearch.com: What is this testing prescribed for?
Response: Caris Molecular Intelligence® identifies key molecular features of cancer and provides clinical insights to aid oncologists in personalizing cancer therapies for their solid tumor cancer patients.
MedicalResearch.com: Is there anything else you would like to add?
Response: Caris has also submitted Pre-Market Approval (PMA) applications for MI Exome™ CDx and MI Transcriptome™ CDx to the U.S. Food and Drug Administration (FDA). MI Exome™ CDx, whole exome sequencing (DNA), and MI Transcriptome™ CDx, whole transcriptome sequencing (RNA), are powerful precision medicine assays that include key companion diagnostic biomarkers with therapy claims, and detect all classes of alterations including genomic signatures for microsatellite instability (MSI), tumor mutation burden (TMB), and loss of heterozygosity (LOH).
Caris Life Sciences Launches Whole Exome Sequencing with MI Exome
April 22, 2020
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.